Escolar Documentos
Profissional Documentos
Cultura Documentos
adverse effect
afterload
resistance that ventricles must work against to eject blood into the aorta during systole.
agranulocytosis
sudden drop in leukocyte count; often followed by a severe infection manifested by high
fever, chills, prostration, and ulcerations of mucous membrane such as in the mouth,
rectum, or vagina.
akathisia
analeptic
restorative medication that enhances excitation of the CNS without affecting inhibitory
impulses.
anaphylactoid reaction
anticholinergic actions
bioavailability
fraction of active drug that reaches its action sites after administration by any route.
Following an IV dose, bioavailability is 100%; however, such factors as first-pass effect,
enterohepatic cycling, and biotransformation reduce bioavailability of an orally
administered drug.
blood dyscrasia
cardiotoxicity
cholinergic response
circulatory overload
CNS stimulation
CNS toxicity
Cushing’s syndrome
fatty swellings in the interscapular area (buffalo hump) and in the facial area (moon face),
distension of the abdomen, ecchymoses following even minor trauma, impotence,
amenorrhea, high blood pressure, general weakness, loss of muscle mass, osteoporosis,
and psychosis.
dehydration
disulfiram-type reaction
enzyme induction
first-pass effect
drug-induced circumscribed skin lesion that persists or recurs in the same site. Residual
pigmentation may remain following drug withdrawal.
half-life (t½)
time required for concentration of a drug in the body to decrease by 50%. Half-life also
represents the time necessary to reach steady state or to decline from steady state after a
change (i.e., starting or stopping) in the dosing regimen. Half-life may be affected by a
disease state and age of the drug user.
heat stroke
a life-threatening condition manifested by absence of sweating; red, dry, hot skin; dilated
pupils; dyspnea; full bounding pulse; temperature above 40° C (105° F); and mental
confusion.
hepatic toxicity
hyperammonemia
hypercalcemia
elevated serum calcium manifested by deep bone and flank pain, renal calculi, anorexia,
nausea, vomiting, thirst, constipation, muscle hypotonicity, pathologic fracture,
bradycardia, lethargy, and psychosis.
hyperglycemia
elevated blood glucose manifested by flushed, dry skin, low blood pressure and elevated
pulse, tachypnea, Kussmaul’s respirations, polyuria, polydipsia; polyphagia, lethargy, and
drowsiness.
hyperkalemia
hypermagnesemia
excessive magnesium in blood, which may produce cathartic effect, profound thirst,
flushing, sedation, confusion, depressed deep tendon reflexes (DTRs), muscle weakness,
hypotension, and depressed respirations.
hypernatremia
hyperthyroidism
excessive secretion by the thyroid glands, which increases basal metabolic rate, resulting
in warm, flushed, moist skin; tachycardia, exophthalmos; infrequent lid blinking; lid
edema; weight loss despite increased appetite; frequent urination; menstrual irregularity;
breathlessness; hypoventilation; congestive heart failure; excessive sweating.
hyperuricemia
excessive uric acid in blood, resulting in pain in flank; stomach, or joints, and changes in
intake and output ratio and pattern.
hypocalcemia
abnormally low calcium level in blood, which may result in depression; psychosis;
hyperreflexia; diarrhea; cardiac arrhythmias; hypotension; muscle spasms; paresthesias of
feet, fingers, tongue; positive Chvostek’s sign. Severe deficiency (tetany) may result in
carpopedal spasms, spasms of face muscle, laryngospasm, and generalized convulsions.
hypoglycemia
abnormally low glucose level in the blood, which may result in acute fatigue,
restlessness, malaise, marked irritability and weakness, cold sweats, excessive hunger,
headache, dizziness, confusion, slurred speech, loss of consciousness, and death.
hypokalemia
abnormally low level of potassium in blood, which may result in malaise, fatigue,
paresthesias, depressed reflexes, muscle weakness and cramps, rapid, irregular pulse,
arrhythmias, hypotension, vomiting, paralytic ileus, mental confusion, depression,
delayed thought process, abdominal distension, polyuria, shallow breathing, and
shortness of breath.
hypomagnesemia
hypophosphatemia
abnormally low level of phosphates in blood, resulting in muscle weakness, anorexia,
malaise, absent deep tendon reflexes, bone pain, paresthesias, tremors, negative calcium
balance, osteomalacia, osteoporosis.
hypothyroidism
condition caused by thyroid hormone deficiency that lowers basal metabolic rate and may
result in periorbital edema, lethargy, puffy hands and feet, cool, pale skin, vertigo,
nocturnal cramps, decreased GI motility, constipation, hypotension, slow pulse,
depressed muscular activity, and enlarged thyroid gland.
hypoxia
measurement that normalizes for the differences obtained from various laboratory
readings in the value for thromboplastin blood level.
leukopenia
abnormal decrease in number of white blood cells, usually below 5000 per cubic
millimeter, resulting in fever, chills, sore mouth or throat, and unexplained fatigue.
liver toxicity
metabolic acidosis
metabolic alkalosis
increase in pH value of the extracellular fluid caused by either a loss of acid from the
body (e.g., through vomiting) or an increased level of bicarbonate ions (e.g., through
ingestion of sodium bicarbonate). It may result in muscle weakness, irritability,
confusion, muscle twitching, slow and shallow respirations, and convulsive seizures.
microsomal enzymes
drug-metabolizing enzymes located in the endoplasmic reticulum of the liver and other
tissues chiefly responsible for oxidative drug metabolism, e.g., cytochrome P450.
myopathy
nephrotoxicity
impairment of the nephrons of the kidney manifested by one or more of the following:
oliguria, urinary frequency, hematuria, cloudy urine, rising BUN and serum creatinine,
fever, graft tenderness or enlargement.
orphan drug
(as defined by the Orphan Drug Act, an amendment of the Federal Food, Drug, and
Cosmetic Act which took effect in January 1983): drug or biological product used in the
treatment, diagnosis, or prevention of a rare disease. A rare disease or condition is one
that affects fewer than 200,000 persons in the United States, or affects more than 200,000
persons but for which there is no reasonable expectation that drug research and
development costs can be recovered from sales within the United States.
ototoxicity
impairment of the ear manifested by one or more of the following: headache, dizziness or
vertigo, nausea and vomiting with motion, ataxia, nystagmus.
prodrug
protein binding
pseudomembranous enterocolitis
pseudoparkinsonism
pulmonary edema
excessive fluid in the lung tissue manifestied by one or more of the following: shortness
of breath, cyanosis, persistent productive cough (frothy sputum may be blood tinged),
expiratory rales, restlessness, anxiety, increased heart rate, sense of chest pressure.
renal insufficiency
reduced capacity of the kidney to perform its functions as manifested by one or more of
the following: dysuria, oliguria, hematuria, swelling of lower legs and feet.
serotonin syndrome
Somogyi effect
superinfection
new infection by an organism different from the initial infection being treated by
antimicrobial therapy manifested by one or more of the following: black, hairy tongue;
glossitis, stomatitis; anal itching; loose, foul-smelling stools; vaginal itching or discharge;
sudden fever; cough.
tachyphylaxis
rapid decrease in response to a drug after administration of a few doses. Initial drug
response cannot be restored by an increase in dose.
tardive dyskinesia
vasovagal symptoms
less than normal concentration of sodium in the blood resulting from excess extracellular
and intracellular fluid and producing one or more of the following: lethargy, confusion,
headache, decreased skin turgor, tremors, convulsions, coma, anorexia, nausea, vomiting,
diarrhea, sternal fingerprinting, weight gain, edema, full bounding pulse, jugular vein
distension, rales, signs and symptoms of pulmonary edema.